Abstract: This invention relates to compositions and methods for treating, ameliorating, and preventing the toxic effects of venom poisoning. In particular, the invention provides compositions comprising one or more ruthenim based-agents for one or more of inhibiting venom related procoagulant activity, inhibiting venom related phospholipase A2 (PLA2), and/or inhibiting venom related thrombus generation, and related methods for treating, ameliorating and preventing the toxic effects of venom poisoning in a subject suffering from or at risk of suffering from venom poisoning.

Abstract: This invention relates to compositions and methods for treating, ameliorating and preventing the toxic effects of venom poisoning. In particular, the invention provides compositions comprising carbon monoxide releasing molecules (CORM) or compositions comprising CORM and iron releasing molecules (IRM) for one or more of enhancing coagulation, reducing fibrinolysis, and/or inactivating venom related metalloproteinase activity in a subject suffering from or at risk of suffering from venom poisoning.

Abstract: This invention relates to compositions and methods for treating, ameliorating and preventing the toxic effects of venom poisoning. In particular, the invention provides compositions comprising carbon monoxide releasing molecules (CORM) or compositions comprising CORM and iron releasing molecules (IRM) for one or more of enhancing coagulation, reducing fibrinolysis, and/or inactivating venom related metalloproteinase activity in a subject suffering from or at risk of suffering from venom poisoning.

Abstract: This invention relates to compositions and methods for treating, ameliorating and preventing the toxic effects of venom poisoning. In particular, the invention provides compositions comprising carbon monoxide releasing molecules (CORM) or compositions comprising CORM and iron releasing molecules (IRM) for one or more of enhancing coagulation, reducing fibrinolysis, and/or inactivating venom related metalloproteinase activity in a subject suffering from or at risk of suffering from venom poisoning.

Abstract: Methods for diagnosing or assisting in the diagnosis of iron-related pathologies are provided. The methods are based on the correlation of the degree of iron-specific hypercoagulability with clinical disease. One embodiment provides a method for diagnosing or assisting in diagnosing a subject having or suspected of having an iron-related pathology by analyzing a blood sample obtained from the subject to obtain viscoelastic parameters of the blood sample as the blood sample coagulates. A variation in the viscoelastic parameters of the blood sample relative to a blood sample from a healthy subject indicates the subject has or will likely develop an iron-related pathology. Subjects having an iron-related pathology have viscoelastic parameters that are indicative of enhanced coagulation and/or diminished fibrinolysis compared to the viscoelastic parameters of the blood sample from the healthy subject.

Abstract: This invention relates to compositions and methods for treating, ameliorating and preventing the toxic effects of venom poisoning. In particular, the invention provides compositions comprising carbon monoxide releasing molecules (CORM) or compositions comprising CORM and iron releasing molecules (IRM) for one or more of enhancing coagulation, reducing fibrinolysis, and/or inactivating venom related metalloproteinase activity in a subject suffering from or at risk of suffering from venom poisoning.

Abstract: Methods for diagnosing or assisting in the diagnosis of iron-related pathologies are provided. The methods are based on the correlation of the degree of iron-specific hypercoagulability with clinical disease. One embodiment provides a method for diagnosing or assisting in diagnosing a subject having or suspected of having an iron-related pathology by analyzing a blood sample obtained from the subject to obtain viscoelastic parameters of the blood sample as the blood sample coagulates. A variation in the viscoelastic parameters of the blood sample relative to a blood sample from a healthy subject indicates the subject has or will likely develop an iron-related pathology. Subjects having an iron-related pathology have viscoelastic parameters that are indicative of enhanced coagulation and/or diminished fibrinolysis compared to the viscoelastic parameters of the blood sample from the healthy subject.

Abstract: The present invention provides a method for diagnosing hypercoagulability associated with carbon monoxide exposure in a subject. The method comprises obtaining a plasma sample from the subject, dividing the sample into at least two portions, and determining the clot strength of the first portion. The method further comprises exposing the second portion to an organic reductant, determining the clot strength of the second portion after exposure to the organic reductant, and comparing the clot strength of the first portion with the clot strength of the second portion. A diagnosis of hypercogulability associated with carbon monoxide exposure is made when the clot strength of the second portion is decreased compared with the cloth strength of the first portion.

Abstract: Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichlororuthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).

Abstract: Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).

Abstract: Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).